12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-RSV01: Phase IIb data

Top-line data from 87 lung transplant patients in the intent-to-treat (ITT) population of a double-blind, international Phase IIb trial showed that once-daily 0.6 mg/kg inhaled ALN-RSV01 for 5 days plus standard of care missed the primary endpoint of reducing the incidence of new or progressive bronchiolitis obliterans syndrome at 180 days post-RSV infection vs. placebo plus standard of care (13.2% vs. 28.6%, p=0.052). The ITT population consisted of all patients who received at least 1 dose of study medication. Patients in the ITT population with missing day 180 assessments...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >